1. Home
  2. DRMA vs SKYE Comparison

DRMA vs SKYE Comparison

Compare DRMA & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

N/A

Current Price

$0.58

Market Cap

5.6M

Sector

Health Care

ML Signal

N/A

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

N/A

Current Price

$1.05

Market Cap

6.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DRMA
SKYE
Founded
2014
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
6.4M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
DRMA
SKYE
Price
$0.58
$1.05
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
★ $9.00
AVG Volume (30 Days)
95.3K
★ 102.1K
Earning Date
11-10-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$650.00
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$0.26
52 Week High
$4.66
$11.04

Technical Indicators

Market Signals
Indicator
DRMA
SKYE
Relative Strength Index (RSI) 30.10 40.82
Support Level N/A $0.50
Resistance Level $1.40 $2.28
Average True Range (ATR) 0.09 0.20
MACD -0.01 0.01
Stochastic Oscillator 0.00 58.69

Price Performance

Historical Comparison
DRMA
SKYE

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: